The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

ConditionType2diabetes
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age25-65
SponsorAdrian Vella

About this trial

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

Eligibility criteria

Qualifiers

We will recruit up to 20 weight-stable, subjects with type 2 diabetes

BMI ≥ 28 Kg/M2

Diabetes is managed by diet alone or a combination of oral agents

Disqualifiers

History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.

Active systemic illness or malignancy.

Symptomatic macrovascular or microvascular disease.

Contraindications to MRI (e.g. metal implants, claustrophobia).

Trial design

Treatments tested in this trial

  • Caloric Restriction
  • Hyperglycemic clamp

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

1
Mayo Clinic in Rochester55905, RochesterMinnesota, United States

Sponsors and collaborators

Adrian Vella

Lead sponsor

Mayo Clinic

Sponsor institution